Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
mecbotamab vedotin (BA3011) / BioAtla
2022-000135-23: A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer	Not yet recruiting	2	280	Europe	Mecbotamab Vedotin, Nivolumab, BA3011, BMS-936558, Solution for infusion, Concentrate for solution for infusion, OPDIVO	BioAtla Inc., BioAtla Inc.	Metastatic Non-Small Cell Lung Cancer, Lung Cancer, Diseases [C] - Cancer [C04]
CRI-CCTG-0003/IND.240, NCT04918186: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer	Recruiting	2	60	Canada, US	Durvalumab, BA3011, BA3021, To be determined	Canadian Cancer Trials Group, Cancer Research Institute, New York City, AstraZeneca, BioAtla, Inc.	Ovarian Cancer	12/24	06/25
BA3011-002, NCT04681131: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC	Active, not recruiting	2	240	Europe, US, RoW	CAB-AXL-ADC, BA3011, PD-1 inhibitor	BioAtla, Inc.	Non-Small-Cell Lung Cancer	08/25	08/25
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma	Recruiting	1/2	300	US, RoW	CAB-AXL-ADC, PD-1 inhibitor	BioAtla, Inc.	Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma	12/24	12/24